IL1B and COVID-19: Clinical studies focus on agents that inhibit the IL-1, IL-6, and TNF-α pathways to reduce the risk of coronary heart disease and reduce adverse outcomes after injury, which may also be potentially useful in the treatment of COVID-19 [32].